Sirona Biochem Announces Primate Results for SGLT Inhibitor for Type 2 Diabetes
Vancouver, British Columbia – June 20, 2012 – Sirona
Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced
today results from a preclinical study of its sodium glucose
transporter (SGLT) inhibitor in monkeys. When administered orally,
Sirona Biochem’s SGLT inhibitor, SBM-TFC-039, triggered
glucosuria in a dose-dependent manner. In addition, the glucosuria
effect was robust for the full 24 hours studied.
“At the recent American Diabetes Association meeting in
Philadelphia, it was apparent that SGLT inhibitors are a
potentially ground-breaking treatment for Type 2 diabetes,”
said Dr. Howard Verrico, President and CEO of Sirona Biochem.
“Preclinical results of our SGLT inhibitor, SBM-TFC-039, in
multiple species have consistently demonstrated its efficacy and we
are exploring data that may differentiate SBM-TFC-039 from the
other SGLT inhibitors in development,” he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2
diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption
of glucose into the bloodstream by eliminating excess glucose into
the urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent
diabetic model, in addition to the latest study in primates. In
those tests, SBM-TFC-039 has consistently demonstrated a
glucose-lowering effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes
therapeutics, cancer vaccine antigens, skin depigmenting and
anti-aging agents for cosmetic use, and biological ingredients. The
company utilizes a proprietary chemistry technique to improve
pharmaceutical properties of carbohydrate-based molecules. For more
information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
Posted: June 2012
